

ASX ANNOUNCEMENT

23 May 2023

Results of 2023 Annual Meeting of Stockholders

Sunnyvale, California; 23 May 2023: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), refers to the Annual Meeting of Stockholders held today. The results of the meeting are set out in the attached document in accordance with ASX Listing Rule 3.13.2. All resolutions were decided and passed by way of a poll.

ENDS

This announcement has been authorised for release by Brendan Case, Company Secretary.

For more information, please contact:

Company

John McCutcheon

President & CEO

P: +1 408 720 1906

E: info@ebrsystemsinc.com

Investors

Dean Dribbin

Vesparum Capital

P: +61 3 8582 4800

E: EBRSystems@vesparum.com

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE® Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to

obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

EBR SYSTEMS, INC.
ANNUAL MEETING
Tuesday, 23 May 2023
Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result	If s250U applies
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain	Carried / Not Carried	
Item 1(a) Re-election of Class II Director - Dr Bronwyn Evans	Ordinary	178,245,363 98.40%	0 0.00%	0 0.00%	2,898,713 1.60% (Withheld)	178,245,363 98.40%	0 0.00%	2,898,713 1.60% (Withheld)	Carried	
Item 1(b) Re-election of Class II Director - Mr John McCutcheon	Ordinary	181,084,988 99.97%	0 0.00%	0 0.00%	59,088 0.03% (Withheld)	181,084,988 99.97%	0 0.00%	59,088 0.03% (Withheld)	Carried	
Item 2 Approval of 10% Placement Facility	Special	180,667,074 99.74%	451,502 0.25%	0 0.00%	25,500 0.01%	180,667,074 99.74%	451,502 0.25%	25,500 0.01%	Carried	
Item 3 Grant of Options to Mr John McCutcheon, President, CEO and Executive Director of the Company	Ordinary	100,746,256 96.55%	743,721 0.71%	0 0.00%	2,852,045 2.73%	100,746,256 96.55%	743,721 0.71%	2,852,045 2.73%	Carried	
Item 4 Grant of Options to Mr Allan Will, Executive Chair of the Company	Ordinary	100,676,256 96.49%	813,721 0.78%	0 0.00%	2,852,045 2.73%	100,676,256 96.49%	813,721 0.78%	2,852,045 2.73%	Carried	
Item 5 Grant of Options to Ms Karen Drexler, Non-Executive Director of the Company	Ordinary	100,552,285 96.37%	932,692 0.89%	0 0.00%	2,857,045 2.74%	100,552,285 96.37%	932,692 0.89%	2,857,045 2.74%	Carried	
Item 6 Grant of Options to Dr Bronwyn Evans, Non-Executive Director of the Company	Ordinary	100,515,285 96.30%	974,692 0.93%	0 0.00%	2,889,082 2.77%	100,515,285 96.30%	974,692 0.93%	2,889,082 2.77%	Carried	
Item 7 Grant of Options to Mr Trevor Moody, Non-Executive Director of the Company	Ordinary	100,552,285 96.37%	932,692 0.89%	0 0.00%	2,857,045 2.74%	100,552,285 96.37%	932,692 0.89%	2,857,045 2.74%	Carried	
Item 8 Grant of Options to Dr David Steinhaus, Non-Executive Director of the Company	Ordinary	100,552,285 96.37%	932,692 0.89%	0 0.00%	2,857,045 2.74%	100,552,285 96.37%	932,692 0.89%	2,857,045 2.74%	Carried	
Item 9 Grant of Options to a Nominated Entity of Dr Christopher Nave, Non- Executive Director of the Company	Ordinary	100,464,785 96.28%	1,020,192 0.98%	0 0.00%	2,857,045 2.74%	100,464,785 96.28%	1,020,192 0.98%	2,857,045 2.74%	Carried	

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.